MX2020005187A - Compuestos y composiciones farmaceuticas antivirales, asi como metodos de uso de los mismos. - Google Patents

Compuestos y composiciones farmaceuticas antivirales, asi como metodos de uso de los mismos.

Info

Publication number
MX2020005187A
MX2020005187A MX2020005187A MX2020005187A MX2020005187A MX 2020005187 A MX2020005187 A MX 2020005187A MX 2020005187 A MX2020005187 A MX 2020005187A MX 2020005187 A MX2020005187 A MX 2020005187A MX 2020005187 A MX2020005187 A MX 2020005187A
Authority
MX
Mexico
Prior art keywords
pharmaceutical compositions
methods
viral compounds
compounds
viral infection
Prior art date
Application number
MX2020005187A
Other languages
English (en)
Inventor
Shawn P Iadonato
Kerry W Fowler
Kristin M Bedard
Ikenna Madu
Shari Kaiser
Original Assignee
Kineta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kineta Inc filed Critical Kineta Inc
Publication of MX2020005187A publication Critical patent/MX2020005187A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se describen en la presente, compuestos, composiciones farmacéuticas y métodos relacionados útiles para el tratamiento de una infección viral, que incluye una infección de ARN viral en sujetos. Los compuestos, composiciones farmacéuticas y métodos pueden modular la respuesta antiviral inmune innata en células de vertebrados que incluyen activar la trayectoria RIG-I.
MX2020005187A 2014-05-09 2016-11-08 Compuestos y composiciones farmaceuticas antivirales, asi como metodos de uso de los mismos. MX2020005187A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461991418P 2014-05-09 2014-05-09
US201562177900P 2015-03-25 2015-03-25

Publications (1)

Publication Number Publication Date
MX2020005187A true MX2020005187A (es) 2020-08-20

Family

ID=54393071

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016014642A MX2016014642A (es) 2014-05-09 2015-05-08 Compuestos y composiciones farmaceuticas antivirales, asi como metodos de uso de los mismos.
MX2020005187A MX2020005187A (es) 2014-05-09 2016-11-08 Compuestos y composiciones farmaceuticas antivirales, asi como metodos de uso de los mismos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2016014642A MX2016014642A (es) 2014-05-09 2015-05-08 Compuestos y composiciones farmaceuticas antivirales, asi como metodos de uso de los mismos.

Country Status (9)

Country Link
US (3) US9884876B2 (es)
EP (1) EP3139920A4 (es)
JP (1) JP6419313B2 (es)
CN (1) CN106456615B (es)
AU (3) AU2015255714B2 (es)
CA (1) CA2948178A1 (es)
MX (2) MX2016014642A (es)
TW (1) TW201623265A (es)
WO (1) WO2015172099A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019012295A (es) 2017-04-14 2020-02-07 Tollnine Inc Polinucleotidos inmunomoduladores, conjugados de anticuerpos de los mismos y metodos para su uso.
TW202021956A (zh) * 2018-08-09 2020-06-16 美商奇尼塔公司 視黃酸誘導基因"rig-i"途徑之活化劑及其使用方法
TW202035426A (zh) * 2018-08-17 2020-10-01 美商奇尼塔公司 視黃酸誘導基因"rig-i"途徑之活化劑及其使用方法
JP2022506351A (ja) * 2018-11-02 2022-01-17 アイクリス ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト Ｂ型肝炎ウイルス（ｈｂｖ）に対して活性を有する新規ウレア６，７－ジヒドロ－４ｈ－チアゾロ［５，４－ｃ］ピリジン
AU2020289560A1 (en) 2019-06-05 2021-12-23 Emory University Peptidomimetics for the treatment of coronavirus and picornavirus infections
WO2021007283A1 (en) * 2019-07-09 2021-01-14 Regents Of The University Of Minnesota Potentiation of antiviral nucleobases as rna virus therapy
CN114502194A (zh) * 2019-10-02 2022-05-13 华盛顿大学 用于治疗乙型肝炎病毒感染的组合物和方法
MX2022010515A (es) 2020-02-28 2022-11-14 Tallac Therapeutics Inc Conjugacion mediada por transglutaminasa.
CA3177852A1 (en) 2020-04-04 2021-10-07 Pfizer Inc. Methods of treating coronavirus disease 2019
CR20210563A (es) 2020-04-05 2022-01-24 Pfizer Compuestos y métodos para el tratamiento de covid-19
WO2021205296A1 (en) 2020-04-05 2021-10-14 Pfizer Inc. Method of treating covid-19
US20230120707A1 (en) 2020-04-05 2023-04-20 Pfizer Inc. Compounds and Method of Treating COVID-19
US20230293716A1 (en) 2020-05-08 2023-09-21 Bolt Biotherapeutics, Inc. Elastase-substrate, peptide linker immunoconjugates, and uses thereof
CA3178994A1 (en) 2020-05-19 2021-11-25 Iyassu Sebhat Ampk activators
CN113831301B (zh) 2020-06-08 2023-06-06 沈阳药科大学 苯并噻唑类衍生物及其用途
CN116390925A (zh) 2020-06-26 2023-07-04 卡尔优普公司 Ampk活化剂
EP4178955A1 (en) 2020-07-11 2023-05-17 Pfizer Inc. Antiviral heteroaryl ketone derivatives
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
US20230372310A1 (en) * 2020-10-15 2023-11-23 Baden-Württemberg Stiftung Gmbh Flavi-Block: A Pan-Flavivirus Inhibitor
JP2024508817A (ja) * 2021-02-24 2024-02-28 エフ． ホフマン－ラ ロシュ アーゲー Ｂ型肝炎ウイルス感染症の処置および予防のためのベンゾチアゾリルビシクロ［１．１．１］ペンタン誘導体
AU2022244386A1 (en) * 2021-03-24 2023-11-09 Anavex Life Sciences Corp. Prevention and treatment of coronavirus infection
WO2022208262A1 (en) 2021-03-30 2022-10-06 Pfizer Inc. Ether-linked antiviral compounds
TW202343476A (zh) 2022-03-02 2023-11-01 美商輝瑞大藥廠 用於呼吸病況監測及照護之電腦化決策支援工具及醫療裝置

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1024316A (en) * 1911-07-29 1912-04-23 Singer Mfg Co Strip folding and guiding attachment for sewing-machines.
JPS53129036A (en) * 1977-04-18 1978-11-10 Fuji Photo Film Co Ltd Color photographic material
JPH0780355B2 (ja) * 1987-01-22 1995-08-30 富士写真フイルム株式会社 光学的情報記録媒体
GB9923710D0 (en) * 1999-10-08 1999-12-08 Proteus Molecular Design Chemical compounds
WO2004078115A2 (en) * 2003-02-28 2004-09-16 Viropharma, Incorporated Benzothiazole compounds, compositions and methods for treatment and prophylaxis of rotavirus infections and associated diseases
WO2005037845A1 (en) * 2003-10-17 2005-04-28 Rigel Pharmaceuticals, Inc. Benzothiazole and thiazole[5,5-b] pyridine compositions and their use as ubiquitin ligase inhibitors
JP2011504186A (ja) * 2007-11-21 2011-02-03 アボット・ラボラトリーズ カンナビノイド受容体リガンドとしての新規な化合物およびその使用
US8895596B2 (en) * 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
WO2012155352A1 (en) 2011-05-19 2012-11-22 Eli Lilly And Company Dihydroisoxazole compounds, parasiticidal uses and formulations thereof
EP2748172B1 (en) * 2011-09-30 2017-12-06 Kineta, Inc. Anti-viral compounds
US9073946B2 (en) * 2013-01-15 2015-07-07 Kineta, Inc. Anti-viral compounds
CN103193770B (zh) * 2013-03-20 2015-10-28 中国人民解放军第二军医大学 取代苯并噻唑类抗真菌化合物及其制备方法与应用

Also Published As

Publication number Publication date
TW201623265A (zh) 2016-07-01
AU2020201815A1 (en) 2020-04-02
US9884876B2 (en) 2018-02-06
AU2015255714B2 (en) 2019-12-12
CN106456615B (zh) 2020-10-27
WO2015172099A1 (en) 2015-11-12
US20200270274A1 (en) 2020-08-27
EP3139920A1 (en) 2017-03-15
JP2017515901A (ja) 2017-06-15
EP3139920A4 (en) 2017-11-01
CN106456615A (zh) 2017-02-22
US20190002477A1 (en) 2019-01-03
CA2948178A1 (en) 2015-11-12
US20170057978A1 (en) 2017-03-02
MX2016014642A (es) 2017-05-25
AU2020204324A1 (en) 2020-07-16
JP6419313B2 (ja) 2018-11-07
AU2015255714A1 (en) 2016-10-20

Similar Documents

Publication Publication Date Title
MX2020005187A (es) Compuestos y composiciones farmaceuticas antivirales, asi como metodos de uso de los mismos.
MX2022013524A (es) Anticuerpos neutralizantes para el virus de inmunodeficiencia humana.
HUE051986T2 (hu) Helyettesített nukleozidok, nukleotidek és analógjaik virális fertõzés kezelésére való alkalmazásra
PH12017500803A1 (en) Anti-pd-1 antibodies
MX2017005252A (es) Metodos para la preparacion de ribosidos.
MY187540A (en) Compounds active towards bromodomains
PH12015501648B1 (en) 2-aminopyrimidine derivatives for the treatment of viral infections
WO2015153889A3 (en) Materials and methods for the treatment of latent viral infection
EA201791460A1 (ru) N4-гидроксицитидин и связанные с ним производные и варианты противовирусного применения
PH12016502555A1 (en) Methods of preparing substituted nucleotide analogs
PH12017500393A1 (en) Pyrrolopyrimidines for use in influenza virus infection
MY169159A (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
EP3212658A4 (en) 2',2'-dihalo nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
EP3134423A4 (en) 2' -disubstituted nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
MX2017000312A (es) Derivados de isoindolina para usarse en el tratamiento de una infeccion viral.
MX2017003928A (es) Composiciones farmaceuticas de accion prolongada.
HK1252343A1 (zh) 用於治療病毒感染的組合物和方法
MX2017013795A (es) Combinaciones terapeuticas de tratamientos antivirales y antiinflamatorios.
WO2014113492A3 (en) Anti-viral compounds
PH12015502564A1 (en) Pyridone derivatives for the treatment of viral infections and further diseases
PH12017500816A1 (en) Long acting pharmaceutical compositions for hepatitis c
PH12017500820A1 (en) Combination long acting compositions and methods for hepatitis c
SG10201903630UA (en) Iminosugars useful for the treatment of viral diseases
MX2017001512A (es) Compuestos activos hacia bromodominios.
TH1501007495A (th) อนุพันธ์ไพร์โรโล [3,2-d] ไพริมิดีนสำหรับการรักษาการติดเชื้อไวรัสและโรคอื่นๆ